Risk of changes to the medical and nursing care fee systems
First written in FY2016. 11 of 24 entries say "Restated". Latest entry: 2026-11-12.
TOKAI Corp. moved to the "Worse" side of this theme in 2021, 5 years before the typical company in this theme (2026).
The whole theme swung hardest in 2026: 8 of 17 companies on the "Worse" side.
0 other companies' latest entry also says "Advanced".
- FY2026RestatedAnnual report
「The major risks include the risk of revisions to the social security system and other changes, and the risk relating to securing human resources. The company describes the outlines of these risks below.」
The company continues to position the risk of revisions to the social security system, including medical fees, drug prices and the Long-Term Care Insurance Act, as a major risk material to investors' decisions. - FY2025-H1MaterialisedAnnual report
「In terms of profit, although technical fee revenue increased as a result of strengthening primary pharmacy functions, cost of sales rose against a backdrop of drug price revisions and tight pharmaceutical supplies. Labor and personnel expenses also increased following a review of the pay structure prompted by revisions to medical service fees. As a result, profit declined from the previous interim consolidated accounting period.」
Higher costs resulting from drug price revisions and tight pharmaceutical supplies emerged in the interim period's results as factors reducing pharmacy service profit. Pharmacy service operating profit declined 23.4% year on year for the interim period. - FY2024RestatedAnnual report
「Among the matters concerning the business and accounting conditions described in the annual securities report, the major risks considered potentially capable of having a material impact on investors' decisions include the risk of revisions to the social security system and other changes, and the risk relating to securing human resources. The company describes the outlines of these risks below.」
The company continues to position the risk of revisions to the social security system, including changes to medical fees, drug prices and the Long-Term Care Insurance Act, as a major risk material to investment decisions, and describes efforts to minimize the impact through execution of its business strategy and information gathering. - FY2023-Q3RestatedAnnual report
「In terms of profit, although higher sales contributed to profit growth, profit declined year on year because costs increased against the backdrop of drug-price revisions and tight pharmaceutical supplies.」
Higher costs resulting from drug price revisions and tight pharmaceutical supplies continue to be reflected in actual results as factors reducing pharmacy service profit. - FY2023-Q2MaterialisedAnnual report
「In terms of profit, although higher sales contributed to profit growth, profit declined year on year because costs increased against the backdrop of drug-price revisions and tight pharmaceutical supplies.」
In addition to the impact of drug price revisions previously described as a risk from regulatory changes, higher costs resulting from tight pharmaceutical supplies have actually emerged in results as a factor reducing pharmacy service profit. - FY2021ReframedAnnual report
「In Japan, as controlling medical and nursing care costs has become an urgent issue against a backdrop of population aging progressing at a pace unprecedented in other countries, major changes to the social security system resulting from legal amendments or other measures could affect the Group's operating performance, as it operates its core businesses in the healthcare industry.」
The risk previously described as the risk of revisions to medical and nursing care fees has been organized as the broader risk of revisions to the social security system against a backdrop of efforts to control medical and nursing care costs. The company also specifies revisions to nursing care fees, the Long-Term Care Insurance Act, medical fees and drug prices, as well as indirect impacts on contracted services. - FY2019-Q3RestatedAnnual report
「While pharmacy service revenue declined year on year for the same quarter due to the impact of the medical fee revision, the health and lifestyle services and environmental services businesses performed steadily.」
The decline in pharmacy service revenue resulting from the medical fee revision continues to be reflected in actual results. - FY2019-Q2RestatedAnnual report
「While pharmacy service revenue declined year on year for the same quarter due to the impact of the medical fee revision, the health and lifestyle services and environmental services businesses performed steadily.」
The decline in pharmacy service revenue resulting from the medical fee revision continues to be reflected in actual results. Pharmacy service revenue declined 3.6% year on year for the same quarter, and operating profit declined 39.3%. - FY2019-Q1MaterialisedAnnual report
「Medical and nursing-care fees were revised simultaneously in April 2018, and the environment surrounding our Group changed rapidly.」
Revisions to medical and nursing care fees, which had long been disclosed as risks from changes to the regulatory system, were implemented, and their actual impact included lower pharmacy service revenue and profit. - FY2018RestatedAnnual report
「The healthcare industry in which our Group operates its core businesses is required to respond appropriately to changes in the business environment, given the frequency of additions and changes to national policies accompanying population aging, including medical fee revisions every 2 years and nursing-care fee revisions every 3 years.」
Changes in the business environment resulting from periodic revisions to medical and nursing care fees and changes in government policies continue to be treated as risks. - FY2017RestatedAnnual report
「In April 2016, medical fees were revised, and the environment surrounding the Group's businesses, particularly its pharmacy services, has been undergoing significant changes.」
The company continues to report in its annual results that the medical fee revision resulted in lower pharmacy service revenue and profit. - FY2017-Q3RestatedAnnual report
「Dispensing services recorded lower revenue due to the impact of medical fee revisions, including reductions in drug prices.」
The company continues to report as an actual result a decline in pharmacy service revenue resulting from the medical fee revision, particularly the reduction in drug prices. - FY2017-Q2RestatedAnnual report
「On the earnings front, despite a decline in pharmacy service profit due to the negative impact of the medical fee revision and an increase in personnel and other expenses to strengthen sales capabilities, operating profit, ordinary profit and net income attributable to owners of the parent increased year on year for the same quarter, owing to higher profit accompanying increased sales in the health and lifestyle services business, the deferral of some rental materials costs to the second half, and lower fuel costs resulting from the decline in crude oil prices.」
The decline in pharmacy service profit resulting from the medical fee revision continues to be reported in actual results, reaffirming the impact of a regulatory change that has already materialized. - FY2017-Q1MaterialisedAnnual report
「In April 2016, medical fees were revised, and the environment surrounding the Group's businesses, particularly its pharmacy services, has been undergoing significant changes.」
The previously disclosed risk of changes to the medical fee system materialized when medical fees were revised, and an actual decline in pharmacy service profit was reported. - FY2016First statedAnnual report
「The business environment is subject to frequent changes, including medical fee revisions every 2 years, nursing care fee revisions every 3 years, and additions or changes to government policies accompanying the progression of population aging. The company is therefore required to respond appropriately to changes in the business environment.」
The company describes the risk that changes in laws and regulations and government policies, including the frequency of medical and nursing care fee revisions, may affect customers and earnings.